ADOPORT, commonly known by its generic name Tacrolimus, is a potent immunosuppressive medication primarily used to prevent organ rejection in patients who have undergone organ transplants, such as kidney, liver, or heart transplants. It works by inhibiting the activity of certain immune cells that would normally attack the transplanted organ, thus reducing the risk of rejection. ADOPORT belongs to a class of drugs known as calcineurin inhibitors and is usually administered orally in capsule form, although it can also be given intravenously in certain clinical situations. The dosage and duration of treatment with ADOPORT are carefully determined by healthcare professionals based on the patient's medical condition, response to treatment, and, in some cases, body weight. While effective in preventing organ rejection, ADOPORT can have significant side effects and requires close monitoring by healthcare providers to manage potential risks and ensure the best possible outcome for the patient.